Trials / Completed
CompletedNCT00777868
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 135 (actual)
- Sponsor
- Dow Pharmaceutical Sciences · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and effectiveness of two concentrations of IDP-108 in treating patients with onychomycosis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Low Strength IDP-108 | Topical application once a day for 9 months |
| DRUG | High Strength IDP-108 | Topical application once a day for 9 months |
| DRUG | High Strength IDP-108 under occlusion | Topical application once a day for 9 months |
| DRUG | Vehicle | Topical application once a day for 9 months |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2009-04-01
- Completion
- 2009-04-01
- First posted
- 2008-10-22
- Last updated
- 2012-06-22
Locations
10 sites across 1 country: Mexico
Source: ClinicalTrials.gov record NCT00777868. Inclusion in this directory is not an endorsement.